RMTI · Rockwell Medical, Inc.

Summary

Rockwell Medical, Inc. announced fourth quarter and full-year 2025 financial results with Q4 net sales of $18.3 million versus $24.7 million in Q4 2024, gross margin of 21% versus 15%, and full-year net sales of $69.3 million, gross margin of 17%, and Adjusted EBITDA of $0.3 million. The company reported $25.0 million in cash at year-end and issued 2026 guidance for $1-2 million Adjusted EBITDA.

Key takeaways

• Q4 2025 net sales $18.3 million versus $24.7 million Q4 2024
• Q4 2025 gross margin 21% versus 15% Q4 2024
• Full-year 2025 net sales $69.3 million versus $101.5 million 2024
• Full-year 2025 gross margin 17%
• Full-year 2025 Adjusted EBITDA $0.3 million
• Cash and cash equivalents and investments available-for-sale $25.0 million at December 31, 2025